Mechanisms of disease: Toll-like receptors in cardiovascular disease

被引:253
作者
Frantz, Stefan [1 ]
Ertl, Georg [1 ]
Bauersachs, Johann [1 ]
机构
[1] Univ Wurzburg, Med Klin & Poliklin 1, Herzkreislauf Zentrum, D-97080 Wurzburg, Germany
来源
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE | 2007年 / 4卷 / 08期
关键词
atherosclerosis; heart failure; innate immunity; Toll-like receptors;
D O I
10.1038/ncpcardio0938
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The innate immune system detects highly conserved, relatively invariant structural motifs of pathogens. Toll-like receptors (TLRs) have been identified as the primary innate immune receptors. TLRs distinguish between different patterns of pathogens and activate a rapid innate immune response; however, TLRs can also be activated by host-derived molecules. In addition to being expressed in immune cells, TLRs are expressed in other tissues, such as those of the cardiovascular system. TLRs could, therefore, be a key link between cardiovascular disease development and the immune system. Indeed, evidence that TLR activation contributes to the development and progression of atherosclerosis, cardiac dysfunction in sepsis, and congestive heart failure, is convincing. Although much has been learned about TLR activation in cellular components of the cardiovascular system, the role individual TLR family members have in the pathophysiology of cardiovascular diseases and hence in clinical practice remains to be defined. Here we review the rapid progress that has been made in this field, which has improved our understanding of vascular as well as myocardial TLR function in basic and clinical science.
引用
收藏
页码:444 / 454
页数:11
相关论文
共 77 条
  • [71] Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the Toll/interleukin-1 receptor signaling pathway in innate immune cells
    Vabulas, RM
    Ahmad-Nejad, P
    da Costa, C
    Miethke, T
    Kirschning, CJ
    Häcker, H
    Wagner, H
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (33) : 31332 - 31339
  • [72] Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial
    Vanags, Daina
    Williams, Bronwyn
    Johnson, Barbara
    Hall, Stephen
    Nash, Peter
    Taylor, Andrew
    Weiss, Julissa
    Feeney, Dennis
    [J]. LANCET, 2006, 368 (9538) : 855 - 863
  • [73] Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL
    Xu, XH
    Shah, PK
    Faure, E
    Equils, O
    Thomas, L
    Fishbein, MC
    Luthringer, D
    Xu, XP
    Rajavashisth, TB
    Yano, J
    Kaul, S
    Arditi, M
    [J]. CIRCULATION, 2001, 104 (25) : 3103 - 3108
  • [74] TLR4 Asp299Gly polymorphism is not associated with coronary artery stenosis
    Yang, IA
    Holloway, JW
    Ye, S
    [J]. ATHEROSCLEROSIS, 2003, 170 (01) : 187 - 190
  • [75] Toll-like receptor 4 Asp299Gly gene polymorphism and risk of atherothrombosis
    Zee, RYL
    Hegener, HH
    Gould, J
    Ridker, PM
    [J]. STROKE, 2005, 36 (01) : 154 - 157
  • [76] TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice
    Zhang, D
    Gaussin, V
    Taffet, GE
    Belaguli, NS
    Yamada, M
    Schwartz, RJ
    Michael, LH
    Overbeek, PA
    Schneider, MD
    [J]. NATURE MEDICINE, 2000, 6 (05) : 556 - 563
  • [77] MyD88 and NOS2 are essential for Toll-like receptor 4-mediated survival effect in cardiomyocytes
    Zhu, Xinsheng
    Zhao, Huailong
    Graveline, Amanda R.
    Buys, Emmanuel S.
    Schmidt, Ulrich
    Bloch, Kenneth D.
    Rosenzweig, Anthony
    Chao, Wei
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2006, 291 (04): : H1900 - H1909